Capitolis Advisors LLC Gilead Sciences, Inc. Transaction History

Capitolis Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$57.92 - $72.58 $3.32 Million - $4.17 Million	-57,393 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$64.88 - $73.64 $1.03 Million - $1.17 Million	15,854 Added 38.17%	57,393 $4.17 Million
Q3 2021 Nov 12, 2021	BUY	$67.69 - $73.03 $2.58 Million - $2.79 Million	38,166 Added 1131.51%	41,539 $2.74 Million
Q2 2021 Aug 11, 2021	SELL	$63.47 - $69.35 $4.42 Million - $4.83 Million	-69,671 Reduced 95.38%	3,373 $232,000
Q4 2020 May 07, 2021	BUY	$56.65 - $64.55 $4.14 Million - $4.71 Million	73,044 New	73,044 $4.26 Million

1,942

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $117B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Capitolis Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Capitolis Advisors LLC with notifications on news.